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T cell costimulatory pathways regulate T cell 
activation and tolerance (1–3). Costimulation 
provides a second signal to T cells in conjunc-
tion with signaling through TCR. The well-
characterized costimulatory molecules B7-1 
and B7-2 augment and sustain T cell responses 
through binding to the CD28 costimulatory 
receptor. B7-1 and B7-2 also bind CTLA-4, 
a second, higher affi   nity receptor that provides 
inhibitory signals to T cells and regulates self-
reactive T cells (4, 5). The B7/CD28 superfam-
ily has expanded to include other costimulatory 
and inhibitory receptors, including inducible 
costimulator (ICOS) and programmed death 1 
(PD-1), which are inducibly expressed on the 
surface of T cells and provide unique secondary 
signals that shape the immune response (6, 7).
There is mounting evidence that PD-1 
plays a crucial role in peripheral tolerance (8). 
PD-1 expression is induced upon the acti-
vation of peripheral T and B cells as well as 
monocytes. The functional signifi  cance  of 
the PD-1 inhibitory signal is demonstrated by 
the phenotype of PD-1–defi  cient (PD-1−/−) 
mice. PD-1−/− mice develop features of a 
  lupus-like disease on the C57BL/6 background 
and a dilated cardiomyopathy on the BALB/c 
background. These fi  ndings suggest that PD-1 
may inhibit T and/or B cell activation and is 
important in regulating tolerance.
PD-1 has two ligands with distinct expres-
sion patterns: PD-1 ligand 1 (PD-L1; B7-H1) 
and PD-L2 (B7-DC). PD-L1 is expressed on 
resting T cells, B cells, DCs, and macrophages 
and is further up-regulated upon activation. 
PD-L1 is also expressed on parenchymal cells, in-
cluding vascular endothelial cells and pancreatic 
islet cells (9–12). In contrast, PD-L2 is induc-
ibly expressed only on DCs and   macrophages 
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(13, 14). The distinct expression patterns of PD-L1 and 
PD-L2 suggest that their relative functions may depend on 
the tissue microenvironment. The expression of PD-L1 on 
nonhematopoietic cells is particularly intriguing because it 
suggests that PD-L1 may regulate potentially self-reactive 
T cell responses in target organs and/or control the extent of 
pathogenic eff  ector T cell–mediated infl  ammatory responses 
within tissues.
Whether PD-L1 and PD-L2 have overlapping or distinct 
functions is under active investigation. Some studies have 
suggested that PD-L1 and PD-L2 inhibit T cell proliferation 
and cytokine production (13, 15), whereas others support a 
stimulatory role for the PD-Ls (14, 16). The phenotype of 
PD-L1−/− mice demonstrates that PD-L1 has a critical nega-
tive regulatory role in vivo in inhibiting the expansion of 
CD4+ and CD8+ IFN-γ+–producing cells (15). To evalu-
ate the obligatory functions of PD-L1 and PD-L2 in vivo, 
we generated mice defi   cient in both PD-L1 and PD-L2 
(PD-L1/L2−/−). Comparative analyses of PD-L1/L2−/− mice 
and mice lacking either PD-L1 or PD-L2 provide a means 
to ascertain unique as well as overlapping functions for these 
two PD-Ls. In this study, we compare the roles of PD-L1 
and PD-L2 in regulating CD4+ T cell activation and toler-
ance using mice lacking PD-L1 and/or PD-L2. To evalu-
ate the functional signifi  cance of PD-L1 expression in the 
pancreas, we backcrossed mice lacking PD-L1 and/or PD-L2
onto the non-obese diabetic (NOD) background and 
  analyzed the roles of these molecules in spontaneous T cell–
mediated autoimmune diabetes. We evaluated the requirement
for PD-L1 and PD-L2 expression on hematopoietic versus 
parenchymal cells by transferring prediabetic T cells into WT 
or PD-L1/PD-L2−/− NOD SCID mice or into BM chi-
meras that expressed PD-L1 and PD-L2 solely on cells of 
nonlymphoid hematopoietic origin. The function of PD-L1 
on islets was probed in islet transplant experiments using WT 
versus PD-L1/PD-L2−/− syngeneic islet cells. Our studies 
demonstrate that PD-L1 and PD-L2 have overlapping roles 
in inhibiting CD4+ T cell eff  ector cytokine production in 
lymphoid tissues, particularly in limiting IFN-γ production. 
However, we fi  nd a unique role for PD-L1 in inhibiting self-
reactive T cell responses and protecting the pancreas from 
T cell–mediated tissue damage. Thus, PD-L1 is a key mediator 
of tissue tolerance.
RESULTS
Generation and characterization 
of PD-L2– and PD-L1/PD-L2–defi  cient mice
To evaluate the essential functions of PD-L1 and PD-L2 in 
vivo, we generated mice lacking PD-L2 or both PD-L1 and 
PD-L2 (Fig. 1, A and B; and Fig. S1, available at http://www.
jem.org/cgi/content/full/jem.20051776/DC1). Although 
mice lacking PD-L1 or PD-L2 have been described by our 
laboratory (15, 17) and others (18, 19), this is the fi  rst study of 
mice lacking both ligands. The PD-L2–targeting vector re-
placed the IgV exon of the PD-L2 gene with the hygromycin 
drug resistance gene (Fig. 1 A). Because mouse PD-L1 and 
PD-L2 are closely linked on mouse chromosome 19, PD-L2 
was targeted in PD-L1+/− embryonic stem (ES) cells (15) 
to generate a mouse strain lacking both PD-L1 and PD-L2 
(Fig. 1 B). The absence of PD-L1 and/or PD-L2 expression 
was confi  rmed by evaluating PD-L1 and PD-L2 expression 
on BM-derived DCs (BM-DCs) from WT, PD-L1−/−, 
PD-L2−/−, and PD-L1/L2−/− mice (Fig. 1 C). PD-L1−/− 
BM-DCs did not express PD-L1 and had levels of PD-L2 
similar to those of WT. PD-L2 was not detected on PD-L2−/− 
BM-DCs, whereas PD-L1 expression was comparable with WT. 
PD-L1/L2−/− DCs did not express PD-L1 or PD-L2. Mouse 
PD-1 Ig did not bind to PD-L1/L2−/− BM-DCs, suggesting 
that there are no additional PD-Ls on BM-DCs (Fig. 1 D).
Lymphocyte development and numbers in the PD-L2−/− 
and PD-L1/PD-L2−/− mice were comparable with WT. 
Flow cytometric analyses revealed similar percentages of 
thymocyte subsets in littermate control WT, PD-L1−/−, 
PD-L2−/−, and PD-L1/L2−/− mice (unpublished data). 
Analyses of spleen and LNs from all four strains revealed 
Figure 1.  Generation of PD-L2−/− and PD-L1/PD-L2−/− mice. 
(A and B) Southern blot analyses performed on WT and PD-L2+/− ES cells 
(A) and PD-L1+/−PD-L2+/− ES cells (B) are shown. For the PD-L1 locus, the 
15.7-kb fragment represents the WT allele, and the 10.1-kb fragment 
represents the disrupted PD-L1 allele. For the PD-L2 locus, the 24.7-kb 
fragment represents the WT allele, and the 13.8-kb fragment represents 
the disrupted allele. (C) WT, PD-L1−/−, PD-L2−/−, and PD-L1/L2−/− BM-DCs 
were generated and evaluated for PD-L1 and PD-L2 expression (shown 
as a solid line; IgG isotype control, shaded histogram). (D) PD-1 Ig does 
not bind to PD-L1/L2−/− DCs. WT (solid line) and PD-L1/L2−/− (dashed 
line) BM-DCs were stained with mouse PD-1 Ig or control Ig, both with 
a human IgG1 Fc region, followed by anti–human IgG-PE. The Ig control 
is shown as a shaded histogram.JEM VOL. 203, April 17, 2006  885
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comparable numbers of T cells (CD4+ and CD8+), Treg 
(CD4+ CD45RBloCD25hi), B cells (CD19+), macrophages 
(F4/80+), neutrophils (CD11b+ GR-1+), and DCs (CD11c+) 
and no spontaneous activation of CD4+ or CD8+ T cells 
(no up-regulation of CD25 or CD69) at 8–12 wk of age 
(unpublished data).
Both PD-L1 and PD-L2 inhibit cytokine production during 
the activation of naive CD4+ T cells
To begin to analyze the roles of PD-L1 and PD-L2 in regu-
lating CD4+ T cell activation and diff  erentiation, we fi  rst iso-
lated naive CD4+ DO11.10 (DO11) T cells and stimulated 
them in vitro with BM-DCs from mice lacking PD-L1 and/or 
PD-L2. Because both PD-L1 and PD-L2 are expressed on 
BM-DCs, these studies enable a direct comparison of the 
two PD-Ls on the same cell type. For these studies, we used 
PD-L1−/−, PD-L2−/−, and PD-L1/PD-L2−/− mice that had 
been backcrossed to BALB/c for seven generations. BM-DCs 
lacking PD-L1 and/or PD-L2 expressed levels of MHC II, 
MHC I, CD80, and CD86 that were comparable with WT 
and produced similar levels of IL-12 in response to LPS, sug-
gesting that there are no intrinsic defects in DC maturation 
or function in the absence of PD-L1 and PD-L2 (unpub-
lished data). Among the four groups, no substantial diff  er-
ences were observed in DO11 T cell proliferation at day 3 
or 5 of stimulation over a range of OVA323–339 concentrations 
(unpublished data). However, IL-2 and IFN-γ production 
were modestly increased (20–50%) in the absence of PD-L1 
or PD-L2 and markedly increased (300–400%) in the absence 
of both PD-L1 and PD-L2 (Fig. 2 A). Only a low level of 
IL-4 production was observed in these cultures. IL-4 produc-
tion was comparable among WT, PD-L1−/−, and PD-L2−/− 
BM-DCs but was reduced in PD-L1/PD-L2−/−–stimulated 
cultures (unpublished data). These data suggest that PD-L1 
and PD-L2 have overlapping roles in limiting IL-2 and IFN-γ 
production during naive CD4+ T cell activation.
To compare the roles of PD-L1 and PD-L2 in regulat-
ing CD4+ T cell responses in vivo where they are distinctly 
expressed, we used the DO11 adoptive transfer model (20). 
Naive DO11 CD4+ cells were isolated and adoptively trans-
ferred into WT, PD-L1−/−, PD-L2−/−, or PD-L1/L2−/− 
recipients, which were immunized with OVA emulsifi  ed in 
IFA. Similar to our in vitro fi  ndings, DO11 T cell expansion 
did not diff  er substantially among the groups (unpublished 
data). Cytokine production was measured by ELISA after 
restimulation of DO11 T cells in vitro. DO11 T cells from 
PD-L1/L2−/− adoptive transfer recipients produced signifi  -
cantly increased levels of IL-2 and IFN-γ; IL-2 and IFN-γ 
production were modestly increased in the PD-L1−/− and 
PD-L2−/− groups (Fig. 2 B). Intracellular cytokine staining 
for IFN-γ at day 3 after in vitro stimulation confi  rmed these 
results (unpublished data). IL-4 was below the level of detec-
tion by ELISA, but intracellular cytokine staining showed 
that the DO11+ IL-4+ population was reduced by 56% in 
PD-L1−/− recipients, by 60% in PD-L2−/− recipients, and 
by 86% in PD-L1/L2−/− recipients as compared with WT 
(unpublished data). These data indicate that PD-L1 and 
PD-L2 have overlapping roles in inhibiting proinfl  ammatory 
cytokine production in vivo.
PD-L1/PD-L2−/− mice develop a rapid onset of autoimmune 
diabetes mellitus on the NOD background
The profound increase in proinfl  ammatory cytokine produc-
tion in mice lacking PD-L1 and PD-L2 led us to examine 
the functions of these PD-Ls on T cell responses in a disease 
setting. During the development of autoimmune diabetes in 
NOD mice, PD-L1 is expressed on the islets of Langerhans 
in the pancreas, vascular endothelium, and lymphoid cells as 
well as on APCs, whereas PD-L2 is expressed on activated 
APCs (21, 22). We chose to examine the functional signif-
icance of PD-L1 and PD-L2 in the NOD model of auto-
immune diabetes to dissect the roles of PD-L1 and PD-L2 in 
controlling self-reactive T cells in the immune compartment 
and target tissue.
Because PD-L1 and PD-L2 have overlapping roles in 
controlling proinflammatory cytokine production in the 
DO11 model, we first crossed mice lacking both PD-L1 
and PD-L2 onto the NOD background. PD-L1/PD-L2−/− 
mice were backcrossed four times onto the NOD background 
and fi  xed for homozygosity of the MHC II allele I-Ag7. The 
Figure 2.  PD-L1 and PD-L2 have overlapping roles in limiting IL-2 
and IFN-𝗄 production during naive CD4+ T cell activation. (A) Naive 
DO11 T cells were activated in vitro by WT, PD-L1−/−, PD-L2−/−, and 
PD-L1/L2−/− BM-DCs in the presence of 0–1 μg/ml OVA323–339. To evaluate 
cytokine production, DO11 T cells were activated with 1 μg/ml OVA323–339 
for 5 d, and supernatants were collected every 24 h and assayed by ELISA. 
(B) For in vivo studies, DO11 T cells were purifi  ed and adoptively trans-
ferred into naive WT, PD-L1−/−, PD-L2−/−, or PD-L1/L2−/− hosts and, 24 h 
later, were immunized with 100 μg OVA emulsifi  ed in IFA. 5 d after im-
munization, draining LNs were harvested and stained for KJ126 using the 
clonotypic mAb and CD4, and 105 DO11 cells were restimulated as a whole 
LN culture with 1 μg/ml OVA323–339. Supernatants were collected every 
24 h and assayed for IL-2 and IFN-γ. *, P < 0.05; **, P < 0.005 by the 
unpaired t test. Data shown are representative of at least three experi-
ments. Error bars represent SEM.886  PD-L1 ON PARENCHYMAL CELLS INHIBITS NOD DIABETES | Keir et al.
loss of both PD-Ls resulted in the rapid onset of autoim-
mune disease. PD-L1/PD-L2−/− mice had a signifi  cantly 
earlier onset of hyperglycemia as compared with WT litter-
mate controls (P < 0.0001), on average developing blood 
glucose readings of ≥250 mg/dL by 7.3 wk of age (Fig. 3 A). 
 Interestingly, PD-L1/PD-L2−/− female and male mice 
  developed diabetes with similar kinetics. On average, female 
mice became hyperglycemic at 6.6 wk, whereas male mice 
became diabetic at 7.7 wk of age. Autoimmune diabetes was 
completely penetrant in PD-L1/PD-L2−/− animals, whereas 
only one third of WT female littermates and one tenth of 
WT male littermates had developed autoimmune diabetes by 
40 wk of age. The loss of sex-specifi  c autoimmune eff  ects, 
the increased incidence of disease, and the complete pen-
etrance of autoimmune diabetes in PD-L1/PD-L2−/− NOD 
mice point to an essential role for the PD-Ls in controlling 
peripheral T cell tolerance. These results confi  rm data show-
ing that PD-1−/− NOD mice (23) and NOD mice treated 
with PD-1– or PD-L1–blocking antibodies develop a rapid 
onset of diabetes (21).
PD-L1/PD-L2−/− NOD mice display the early onset 
of insulitis and increased numbers of IFN-𝗄–producing 
CD8+ T cells in the PLN
The striking increase in penetrance and onset of auto-
immune diabetes in PD-L1/PD-L2−/− NOD mice raised 
the question of whether the pathology of autoimmune dia-
betes in the NOD mouse is substantially changed by the loss 
of PD-L1 and PD-L2. We compared the histology of WT 
and PD-L1/PD-L2−/− pancreata from mice between 4 and 
7 wk of age to determine whether the loss of PD-L1 and 
PD-L2 led to any alterations in histopathology. Certain 
hallmarks of diabetes pathology are well known, includ-
ing the development of peri-insulitis in prediabetic animals 
and the expansion of antigen-specifi  c self-reactive T cells in 
the draining pancreatic LN (PLN; reference 1). WT NOD 
mice typically develop peri-insulitis by 3 to 4 wk of age. 
The progression to insulitis, where the islet is infi  ltrated and 
eventually destroyed by leukocytes, is severe in most mice 
by 10 wk of age but does not strictly correspond with dia-
betes incidence (24). Young PD-L1/PD-L2−/− NOD mice 
had signifi   cantly increased insulitis (48% of PD-L1/PD-
L2−/− NOD vs. 0% of WT NOD; P < 0.004) and fewer 
normal islets (34% of PD-L1/PD-L2−/− NOD vs. 84% of 
WT NOD; P < 0.002; Fig. 3, B and C). The cellular com-
position of infl  ammatory infi  ltrates was similar in WT and 
PD-L1/PD-L2−/− NOD mice. The increased number of 
insulitic islets in PD-L1/PD-L2−/− NOD mice refl  ects an 
accelerated disease course.
Remodeling events that occur as part of pancreatic de-
velopment in the mouse result in β cell antigen deposition 
around day 12–14 in the PLN. Self-reactive T cells can be ac-
tivated by DCs bearing β cell antigen and migrate to and/or 
reactivate in the pancreatic islets (25). Therefore, the events 
that occur in the draining LN are critical to the onset of peri-
insulitis and, ultimately, autoimmunity. In the PLN of young 
prediabetic and diabetic PD-L1/PD-L2−/− NOD mice, 
there was a signifi  cant expansion in cell numbers. There was 
no alteration in cell numbers in either the inguinal LN (ILN) 
or spleen, indicating that the expansion and/or increase in 
homing is specifi  c for the PLN. There was a fourfold increase 
Figure 3.  Loss of PD-L1 and PD-L2 results in the rapid onset of 
diabetes and the early onset of insulitis. (A) PD-L1/PD-L2−/− N4 mice 
on the autoimmune diabetes-prone NOD background were monitored for 
the development of hyperglycemia. Animals were scored as diabetic upon 
blood glucose readings of ≥250 mg/dL, and diabetes was confi  rmed by 
three consecutive positive reads. Both female PD-L1/PD-L2−/− NOD mice 
(n = 9) and male PD-L1/PD-L2−/− NOD mice (n = 16) develop autoim-
mune diabetes signifi  cantly (P < 0.0001; unpaired t test) faster than WT 
littermate controls (females, n = 12; males, n = 13). (B) PD-L1/PD-L2−/− 
and WT N5 NOD littermates were analyzed for early and late signs of 
immune cell infi  ltration of the pancreatic islets by histology. Pancreata 
from PD-L1/PD-L2−/− and WT NOD littermates ranging in age from 27 to 
50 d were evaluated histologically. Islets were scored as normal, peri-
insulitic, or insulitic, and the percentage of total islets in each category 
was averaged for each group. Three of nine PD-L1/PD-L2−/− mice were 
hyperglycemic, and all 10 WT animals were euglycemic at the time of 
killing. (C) Representative islets from WT (left; scored as normal) and PD-
L1/PD-L2−/− (right; scored as insulitic) pancreas are shown. Islets pictured 
are from 50-d-old littermate   females with normal blood glucose readings 
immediately before killing.JEM VOL. 203, April 17, 2006  887
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in both CD4+ and CD8+ T cells in the PLN of prediabetic 
PD-L1/PD-L2−/− mice over that of WT NOD controls 
(P ≤ 0.0012; Fig. 4 A). In diabetic mice, there was a   twofold 
increase in both CD4+ and CD8+ T cells in PD-L1/PD-
L2−/− mice compared with WT littermates (P = 0.05 for 
CD4+ cells; Fig. 4 B). There was no signifi  cant change in 
activation markers (CD44 and CD62L) on either CD4+ 
(P = 0.16) or CD8+ (P = 0.58) popu  lations (unpublished 
data). These data demonstrate that the loss of PD-L1 and PD-
L2 leads to an early expansion and/or   increased homing of 
T cells to the PLN, a key site of self-reactive T cell activation 
in the NOD mouse.
Increased T eff  ector cell responses in PD-L1/PD-L2−/− 
NOD mice may contribute to the rapid onset of diabe-
tes. Because the early destruction of pancreatic β cells by 
CD8+ eff  ector cells may contribute to antigen availability 
and progression to autoimmunity, young prediabetic PD-
L1/PD-L2−/− NOD mice and age-matched nondiabetic 
WT littermate controls were evaluated for eff  ector cytokine 
production in the ILN, PLN, pancreas, and spleen (Fig. 4 C
and unpublished data). The percentages of CD8+ T cells 
  secreting either IFN-γ, TNF-α, or both of these proinfl  amma-
tory cytokines in the PLN of prediabetic PD-L1/PD-L2−/− 
NOD mice was two- to threefold greater than in WT NOD 
littermates (Fig. 4 C). There also were more IFN-γ+ CD4+, 
TNF-α+ CD4+, and IFN-γ+ TNF-α+ cells in the PLN of 
prediabetic PD-L1/PD-L2−/− NOD mice. The substan-
tial expansion of pathogenic eff  ector T cells in the PLN of 
PD-L1/PD-L2−/− NOD mice likely contributes to the pre-
cipitated onset of diabetes in these mice.
PD-L1 and PD-L2 expression on nonlymphoid cells controls 
progression to autoimmune diabetes
The rapid onset of diabetes in PD-L1/PD-L2−/− NOD mice 
demonstrates that PD-L1 and PD-L2 expression inhibits the 
development of T cell–mediated spontaneous autoimmune 
diabetes in the NOD mouse. Because of the broad expression 
of the PD-Ls, there are several potential cell types that could 
engage PD-1 on T cells during the development of   diabetes. 
To test whether the expression of PD-L1 and PD-L2 is 
  important on lymphoid or nonlymphoid cells, we generated 
PD-L1/PD-L2−/− NOD SCID mice. These mice provide a 
means to dissect the role of PD-Ls in lymphoid versus non-
lymphoid hematopoietic cells by serving as recipients of lym-
phoid cells from nondiabetic mice.
Autoimmune diabetes can be transferred from prediabetic 
NOD mice to NOD SCID recipients via unfractionated sple-
nocytes. To begin to investigate the roles of PD-L1 and PD-L2 
on nonlymphoid hematopoietic cells in the development of 
diabetes, 2 × 107 splenocytes from prediabetic WT NOD 
mice were adoptively transferred into WT or PD-L1/PD-
L2−/− NOD SCID recipients. WT NOD SCID mice were 
markedly more resistant to diabetes induced by the transfer of 
splenocytes. PD-L1/PD-L2−/− NOD SCID mice progressed 
to diabetes at a mean of 6.5 wk after the adoptive transfer of 
WT splenocytes, whereas WT NOD SCID mice developed 
diabetes >18 wk after WT splenocyte transfer (P < 0.0001 
by unpaired t test; Fig. 5 A). 
B cells are not required for the adoptive transfer of dia-
betes, but there is evidence that antigen presentation by 
B cells contributes to the initiation of T cell–mediated dia-
betes (26, 27). To further probe the role of PD-L1 and 
PD-L2 on nonlymphoid cells in regulating protection 
against diabetes transfer, we examined whether T cells alone 
rapidly transfer diabetes to PD-L1/PD-L2−/− NOD SCID 
mice. 10 million purifi  ed WT NOD T cells, both CD4+ 
and CD8+ cells, were transferred into WT or PD-L1/PD-
L2−/− NOD SCID mice. T cells rapidly transferred disease 
to PD-L1/PD-L2−/− NOD SCIDs with a mean onset of 
diabetes at 6 wk after transfer. In contrast, disease transfer to 
WT NOD SCIDs was delayed, with recipients remaining 
diabetes free >12 wk after adoptive transfer (P = 0.0006 
by unpaired t test; Fig. 5 B). These results indicate that 
PD-L1/PD-L2 expression on nonlymphoid cells is   suffi   cient 
to protect against diabetes.
Expression of PD-L1 and PD-L2 in hematopoietic cells 
is not suffi  cient to prevent the rapid onset of diabetes
We next examined whether PD-L1 and PD-L2 on nonlym-
phoid hematopoietic cells was required to inhibit potentially 
self-reactive T cells. It is possible that PD-L1 and PD-L2 ex-
pression on DCs or other APCs serves to inhibit autoreactive 
T cells at the time of priming in the PLN. Alternatively, the 
expression of PD-L1 within the pancreas might control tissue 
tolerance and prevent potentially self-reactive T cells from 
attacking target cells in the pancreas.
To evaluate the role of PD-L1 and PD-L2 on non-
lymphoid hematopoietic cells, we generated chimeric mice 
that had PD-L1 and PD-L2 expression on nonlymphoid 
hematopoietic cells (such as DCs and NK cells) but not on 
parenchymal cells. Because of a DNA repair defect, NOD 
SCID mice have no B or T cells but have normal popula-
tions of APCs, myeloid cells, and eff  ector cell types such as 
NK cells. BM chimeras were made by lethally irradiating 
PD-L1/PD-L2−/− NOD SCID mice and reconstituting 
them with either WT NOD SCID (chimera B) or PD-
L1/PD-L2−/− NOD SCID (chimera A) BM. The result-
ing chimera B lack PD-L1/PD-L2 expression on all cell 
types except for nonlymphoid hematopoietic cells, which 
have WT levels of PD-L1/PD-L2. We found that chimera 
B animals had similar numbers of CD11c+ DCs in com-
parison with chimera A animals (not depicted) and that 
the expression of PD-L1 and PD-L2 on CD11c+ DCs was 
comparable with WT (Fig. 6, inset; and unpublished data). 
These chimeras were used as recipients for T cells from 
prediabetic NOD mice.
The adoptive transfer of T cells from nondiabetic 
WT NODs into BM chimeras A and B demonstrates that 
PD-L1 and PD-L2 expression on nonlymphoid  hematopoietic 
cells does not protect from the rapid onset of diabetes. The 
onset of diabetes was statistically equivalent between the two 
groups, with a mean onset of 6.7 wk in BM chimera A and 888  PD-L1 ON PARENCHYMAL CELLS INHIBITS NOD DIABETES | Keir et al.
8.2 wk in BM chimera B (P = 0.38 by unpaired t test; Fig. 6). 
These fi  ndings demonstrate that the expression of PD-L1 and 
PD-L2 on DCs and monocytes is not suffi   cient to inhibit 
self-reactive T cells and suggest that the loss of PD-L1 expres-
sion within the pancreas causes accelerated diabetes onset in 
PD-L1/PD-L2−/− NOD mice.
To address the functional signifi  cance of PD-L1 expres-
sion on pancreatic islet cells, we compared the survival of 
islets purifi  ed from WT and PD-L1/PD-L2−/− NOD SCID 
donors after transfer into spontaneously diabetic WT or PD-
L1/PD-L2−/− NOD mice that had been given insulin before 
islet transplant. We transplanted 800–1,000 under the kidney 
capsule and followed blood glucose levels in recipients as a 
means to monitor islet integrity indirectly via the capacity of 
the islets to produce insulin. When the transplant recipients 
became hyperglycemic, they were killed, and their islets 
were evaluated histologically. WT islets survived lon-
ger than PD-L1/PD-L2−/− islets. Histological analyses 
showed that PD-L1/PD-L2−/− islets were more rapidly 
destroyed as compared with WT controls (Table I). A more 
rapid tempo of immune-mediated destruction of PD-L1/PD-
L2−/− islets in diabetic PD-L1/PD-L2−/− NOD recipients is 
suggested by the more rapid progression and resolution of 
infl  ammation and earlier scar formation at the transplant site. 
These data suggest that the expression of PD-L1 on islet cells 
protects against attack by autoreactive T cells.
Figure 4.  Increased T cell numbers and effector function in the PLN 
of PD-L1/PD-L2−/− NOD mice. Lymphocytes from the LNs or spleen of 
prediabetic and diabetic PD-L1/PD-L2−/− NOD mice and WT littermates 
were evaluated by fl  ow cytometry and by restimulation in vitro. (A) Inguinal 
LNs (ILN) and pancreatic LNs (PLN), spleen, and pancreas were taken from 
prediabetic NOD N7 mice (typically between 3–5 wk of age and confi  rmed 
to be nondiabetic by blood glucose of ≤250 mg/dL). Lymphocyte subset 
numbers were calculated by multiplying the total cell yield from an organ 
by the percentage of CD4+ or CD8+ cells by fl  ow cytometry. (B) Lymphoid 
organs from diabetic mice (typically between 5–8 wk of age for N4 PD-L1/
PD-L2−/− and >13 wk for N4 WT; confi  rmed to be diabetic by a blood glu-
cose reading of ≥250 mg/dL) were analyzed as in A. (C) The percentage of 
effector cytokine–producing CD4+ and CD8+ T cells in the PLN is increased 
in young prediabetic PD-L1/PD-L2−/− N7 mice (n = 3) in comparison with 
WT controls (n = 4; P ≤ 0.03 by the unpaired t test). Error bars represent 
SEM. Data are representative of three independent experiments.JEM VOL. 203, April 17, 2006  889
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Expression of PD-L1 and PD-L2 can inhibit diabetogenic 
CD4+ T cells
Diabetes can be transferred to NOD SCID mice by eff  ector 
CD4+ T cells from diabetic mice independently of CD8+ 
T cells. The transfer of diabetogenic CD4+ T cells into 
PD-L1/PD-L2−/− NOD SCID versus WT NOD SCID mice 
allowed us to test whether the expression of PD-L1 and PD-L2 
can actively inhibit diabetes induction by pathogenic eff  ector 
cells. Five million CD4+ T cells from diabetic WT NOD mice 
(blood glucose of ≥250 mg/dL) were adoptively transferred 
into PD-L1/PD-L2−/− NOD SCID or WT NOD SCID mice. 
Recipient PD-L1/PD-L2−/− NOD SCID mice progressed to 
autoimmune diabetes more rapidly than WT NOD SCID 
  recipients, with a mean onset of 5.3 wk in PD-L1/PD-L2−/− 
NOD SCID recipients as compared with 10.5 wk in WT NOD 
SCID recipients (P = 0.005 by unpaired t test; Fig. 7 A). 
To further examine how PD-L1/PD-L2 expression reg-
ulates eff  ector T cell responses, we used T cells isolated from 
pancreatic antigen-specifi  c BDC2.5 TCR transgenic+ (tg+) 
NOD mice in our adoptive transfer system. PD-L1/PD-
L2−/− NOD SCID recipients again developed diabetes more 
rapidly than WT NOD SCID recipients (11.2 vs. 14.8 d;
P < 0.02 by unpaired t test; Fig. 7 B). We compared ef-
fector cytokine produced by BDC2.5 TCR tg+ T cells in 
PD-L1/PD-L2−/− NOD SCID and WT NOD SCID re-
cipients. 7 d after the transfer of 2 × 105 BDC2.5 TCR tg+ 
CD4+CD25−CD62L+ T cells, lymphocytes were isolated 
Figure 5.  PD-L1/PD-L2 expression is required on nonlymphoid 
cells to inhibit the transfer of autoimmune diabetes. Cells isolated 
from nondiabetic WT NOD N5 mice were adoptively transferred into NOD 
SCID N5 mice that either expressed or lacked PD-L1 and PD-L2. (A) 20 × 
106 WT splenocytes effi  ciently induce autoimmune diabetes in PD-L1/PD-
L2−/− NOD SCID mice, whereas disease induction in WT NOD SCID mice is 
signifi  cantly delayed (P < 0.0001 by unpaired t test). (B) 10 × 106 WT 
T cells were transferred i.v. into PD-L1/PD-L2−/− or WT NOD SCID mice. 
PD-L1/PD-L2−/− NOD SCID animals had a signifi  cantly earlier onset of T cell–
mediated autoimmune diabetes (P = 0.0006 by unpaired t test).
Table I. PD-L1 on islets protects against self-reactive T cells 
in diabetic mice
Group (islet donor→
diabetic recipient)
Days to 
rejectiona
Infi  ltrate 
scoreb
Islet 
scorec
PD-L1/PD-L2−/−→WT 74 0
54 0
74 0
24 0
14 0
PD-L1/PD-L2−/−→
PD-L1/PD-L2−/−
11 0
21 0
11 0
21 0
81 0
WT→PD-L1/PD-L2−/− 12 4 0
11 4 1
>57 13
14 4 1
84 0
WT→WT 23 2
33 1
84 1
13 2
26 3 2
15 4 0
aDays to rejection signifi  es the fi  rst day at which a mouse had a blood glucose 
reading of ≥300 mg/dL.
bGraft infi  ltration was scored on a scale of 0–4: 0, no infi  ltration; 1, scattered 
infi  ltrate; 2, some infi  ltrate; 3, scattered islet cells with heavy infi  ltrate; 4, very 
heavy infi  ltration.
cIslet engraftment was scored on a scale of 0–4: 0, scar formation and no evidence 
of any islet tissue; 1, scattered islet cells with heavy infi  ltrate; 2, obvious foci of 
differentiated islet cells despite a heavy infi  ltrate; 3, well-differentiated graft with 
scattered infi  ltrate; 4, large differentiated graft with no infi  ltrate.890  PD-L1 ON PARENCHYMAL CELLS INHIBITS NOD DIABETES | Keir et al.
from the ILN, PLN, and spleen, restimulated in vitro, and 
assayed for the production of IFN-γ and TNF-α. BDC2.5 
TCR tg T cells isolated from PD-L1/PD-L2−/− NOD 
SCID recipients displayed a markedly increased production 
of   proinfl  ammatory cytokines, which is similar to our studies 
of DO11 T cells. Both IFN-γ and TNF-α were increased 
in the ILN and PLN (not depicted and Fig. 7 C). IFN-γ–
producing T cells were doubled, and TNF-α–secreting cells 
were increased fi  vefold in LNs, whereas cells secreting both 
IFN-γ and TNF-α were increased eightfold in the PLN and 
24-fold in the ILN. IFN-γ production was reduced in the 
spleen (unpublished data). Thus, eff  ector cytokine produc-
tion in LNs is enhanced in the absence of PD-L1 and PD-L2. 
Together, these studies demonstrate that diabetogenic eff  ec-
tor CD4+ T cells can be signifi  cantly inhibited by PD-L1 and 
PD-L2 expression and illustrate the functional importance of 
PD-1 ligation on pathogenic T cells.
PD-L1−/− but not PD-L2−/− NOD mice develop a rapid onset 
of autoimmune diabetes
Our data indicate that PD-L1 plays a critical role in tis-
sue tolerance by protecting islets from self-reactive T cells. 
To confi  rm the role that PD-L1 plays in autoimmune diabe-
tes, we crossed mice lacking only PD-L1 or PD-L2 onto 
the NOD background. PD-L1−/− NOD mice displayed an 
indistinguishable phenotype from PD-L1/PD-L2−/− NOD 
mice, with an early onset of autoimmunity, loss of sex-specifi  c 
delays in disease progression, and complete diabetes pene-
trance (Fig. 8 A). In contrast, PD-L2−/− NOD animals did 
not display a more rapid onset of diabetes in comparison with 
WT littermate controls (Fig. 8 B). The PD-L1/PD-L2−/− 
and PD-L1−/− strains were separately backcrossed onto the 
NOD background and provide independent confirmation 
of the importance of PD-L1 in autoimmune diabetes. 
These results are also consistent with studies showing that 
the administration of anti–PD-L1– but not anti–PD-L2–
blocking antibodies induced a rapid onset of autoimmune 
diabetes. Thus, through multiple approaches, we fi  nd that 
PD-L1 expression on parenchymal cells is uniquely respon-
sible for the increased onset and penetrance of autoimmune 
diabetes in PD-L1/PD-L2−/− NOD mice.
DISCUSSION
In this study, we present the initial characterization of mice 
lacking both PD-L1 and PD-L2 and compare them side by 
side with mice lacking either PD-L1 or PD-L2. Analyses of 
these three strains demonstrate important overlapping roles 
for PD-L1 and PD-L2 on APCs in regulating CD4+ T cell 
Figure 6.  PD-L1/PD-L2 expression solely on nonlymphoid hema-
topoietic cells is not suffi  cient to prevent the rapid transfer of 
autoimmune diabetes. PD-L1/PD-L2−/− NOD SCID N5 mice were  
lethally irradiated and reconstituted with BM from WT NOD SCID (chimera B) 
or PD-L1/PD-L2−/− NOD SCID (chimera A) N5 animals. The resulting 
BM chimera B had no PD-L1/PD-L2 expression except on nonlymphoid 
hematopoietic cells such as CD11c+CD3−B220− cells (inset;   dotted 
line, isotype staining). WT NOD N5 T cells were adoptively   trans-
ferred into BM chimeras A and B, which were monitored twice 
weekly for hyper  glycemia. WT NOD T cells transferred autoimmune 
  diabetes to BM   chimeras A and B with similar kinetics (P = 0.38 by 
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responses. We fi  nd that both PD-L1 and PD-L2 can function 
to limit IL-2 and IFN-γ production during the activation 
of naive CD4+ T cells and that they have overlapping roles 
in controlling proinfl  ammatory cytokine production during 
CD4+ T cell activation. In contrast, PD-L1 has a unique 
role in controlling tissue tolerance. PD-L1/PD-L2−/− NOD 
mice of the N4 as well as the N7 and N10 backcross genera-
tions (unpublished data) have a substantially earlier onset of 
clinical diabetes, which is associated with earlier insulitis and 
increased numbers of eff  ector T cells in the PLN. Our studies 
using BM chimeras and islet transplantation point to a novel 
role for PD-L1 in regulating potentially self-reactive T cells 
within the pancreas.
Several of the newer B7 family members, including 
PD-L1, ICOS ligand, B7-H3, and B7-H4(7), are expressed on 
nonhematopoietic cells, but the in vivo signifi  cance of such 
expression has been unclear. Our studies show for the fi  rst 
Figure 7.  Diabetogenic T cells are inhibited by the expression of 
PD-L1/PD-L2 in recipient mice. (A) 5 × 106 CD4+ T cells from diabetic 
WT NOD N5 mice were adoptively transferred into PD-L1/PD-L2−/− or WT 
NOD SCID N5 mice. The onset of diabetes was signifi  cantly delayed in WT 
NOD SCID mice (P = 0.005 by unpaired t test). (B) Sorted naive effector 
CD4+CD25−CD62L+ cells from BDC2.5 TCR tg+ NOD mice (2 × 105 cells) 
were adoptively transferred into PD-L1/PD-L2−/− or WT NOD SCID N5 mice. 
PD-L1/PD-L2−/− NOD SCID recipients had signifi  cantly earlier diabetes 
onset (P = 0.02 by unpaired t test). (C) BDC2.5 TCR tg+ lymphocytes 
were reisolated from PD-L1/PD-L2−/− (n = 4) or WT NOD SCID (n = 4) 
  recipients 7 d after adoptive transfer and restimulated in vitro. CD4+ T cells 
were analyzed for the production of TNF-α and IFN-γ. Production of both 
effector cytokines was signifi  cantly increased in CD4+ cells reisolated 
from PD-L1/PD-L2−/− NOD SCID recipients (P ≤ 0.05 by the unpaired 
t test). The data are representative of three independent experiments. 
Error bars represent SEM. KO, knockout.
Figure 8.  Loss of PD-L1 but not PD-L2 precipitates the rapid 
onset of autoimmune diabetes on the NOD background. PD-L1−/− 
and PD-L2−/− mice were crossed separately onto the autoimmune diabetes–
prone NOD background. Animals were scored as diabetic as in Fig. 1. 
(A) PD-L1−/− NOD mice (equivalent of N4) develop a rapid onset diabetes in 
comparison with WT littermate controls. Both female and male PD-L1−/− 
NOD display a rapid onset of diabetes with complete penetrance. (B) PD-
L2−/− NOD mice (equivalent of N4) do not develop a rapid onset of dia-
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time that the tissue-specifi  c expression of PD-L1 is func-
tionally important and has a key role in protecting against 
pathogenic self-reactive T cells in a target organ. Remark-
ably, BM chimeras that expressed PD-L1 and PD-L2 on he-
matopoietic cells but lacked PD-L1 on all other cell types 
developed early onset diabetes upon T cell transfer. These 
mice have a normal expression of PD-L1 on APCs as well as 
on nonlymphoid eff  ector cells such as NK cells, eosinophils, 
and granulocytes. The rapid onset of autoimmune diabetes 
after the transfer of WT T cells from prediabetic mice into 
these BM chimeras demonstrates that the tissue expression of 
PD-L1 is necessary and suffi   cient to inhibit pathogenic T cell 
responses. In the pancreas, PD-L1 is constitutively expressed 
on pancreatic vascular endothelium at relatively high levels 
(10) and is up-regulated on pancreatic β cells during the de-
velopment of diabetes (21, 22). The rapid destruction of islets 
lacking PD-L1 after transplant into diabetic mice supports 
that PD-L1 expression on islet cells is an important factor in 
controlling tolerance. The factors that govern tissue tolerance 
are not well understood. Our studies identify PD-L1 as a key 
mediator of T cell tolerance within tissues, protecting target 
organs from potentially pathogenic self-reactive T cells.
We fi  nd that PD-L1 is a critical negative regulator of 
self-reactive T cells during both the induction and eff  ector 
phases of diabetes. Our studies indicate that PD-L1 directly 
inhibits self-reactive T cells but do not rule out the possibility 
that PD-L1 may also function through cell extrinsic mecha-
nisms. It appears that the inhibitory signals delivered by 
PD-L1 retard the eff  ector function of self-reactive T cells but 
do not permanently inhibit their responses. Therefore, 
PD-1–PD-L1 interactions may synergize with other inhibi-
tory pathways to regulate the induction and/or maintenance 
of peripheral T cell tolerance. In particular, PD-1 and CTLA-4
appear to have complementary roles in the pathogenesis of 
diabetes. A study with anti–CTLA-4–neutralizing mAb sup-
ports a role for CTLA-4 in the very early stages of disease 
development because CTLA-4 blockade accelerates disease 
progression only if mAbs are administered before the onset of 
insulitis (28). In contrast, PD-1–PD-L1 interactions can in-
hibit both the initiation and progression of diabetes. Previous 
work has shown that treatment of 1–10-wk-old prediabetic 
NOD mice with PD-L1– or PD-1–blocking mAbs precip-
itates diabetes onset (21), which is in contrast to the narrow 
window in which anti–CTLA-4 mAb exerts its eff  ect. In this 
study, we show that PD-L1 can regulate the initial activation 
of potentially pathogenic T cells as well as the responses of 
pathogenic eff  ector T cells.
Studies of the tg overexpression of PD-L1 in pancreatic 
β cells have yielded discordant results. One group reported that 
tg overexpression of PD-L1 in the islets of C57BL/6 mice re-
sults in increased diabetes incidence and posit a costimulatory 
role for PD-L1 (29). A second group has found that tg over-
expression of PD-L1 in the islets of NOD mice results in pro-
tection from autoimmune diabetes (Sytwu, H.-K., and C.-J. 
Wang. 2005. Federation of Clinical Immunology Societies. 
OR-91 [Abstr.]). It is diffi   cult to reconcile these fi  ndings, but 
there is some evidence that genetic background is impor-
tant for the function of the PD-1–PD-L1/PD-L2 pathway 
(8), and the disparity of these fi  ndings may represent a real 
biological eff  ect of PD-L1 overexpression in diff  erent mouse 
strains. Expression of the BDC2.5 tg TCR on the C57BL/6 
background results in an earlier onset of hyperglycemia than 
BDC2.5 tg+ NOD mice (24) and may refl  ect the diff  erences 
in CD4+CD25+ Treg cell numbers on diff  erent genetic back-
grounds (30). It is also possible that particular splice variants 
of PD-1 or PD-Ls may be favored in diabetes-resistant versus 
susceptible genetic backgrounds and infl  uence disease pro-
gression, which is analogous to CTLA-4 (31).   Alternatively, 
a second receptor that binds PD-L1 and PD-L2 has been pro-
posed to be responsible for the costimulatory eff  ect of these 
ligands but has not yet been identifi  ed (32).
Complementary approaches with receptor and ligand-
  defi  cient strains are important for understanding the functions 
of this immunoregulatory pathway. PD-L1−/−, PD-L2−/−, 
and PD-L1/L2−/− mice on the BALB/c background do not 
develop any signs of dilated cardiomyopathy or spontane-
ous mortality up to at least 8 mo of age (unpublished data), 
which is in contrast to PD-1−/− mice (33). These diff  er-
ing phenotypes might refl  ect epistatic interactions between 
flanking DNA in the targeted region and BALB/c DNA. 
It is important to note that the PD-1−/− mouse was made 
using an approach that eliminated the transmembrane do-
main but did not eliminate the ligand-binding domain, leav-
ing some question as to whether the residual binding domain 
is functional in the PD-1−/− mouse. Because PD-1 mRNA 
is made, it is possible that a soluble form of PD-1 is synthe-
sized in the PD-1−/− mouse strain. We have not found any 
evidence for additional PD-Ls. PD-L1/L2−/− DCs did not 
bind PD-1 Ig, but it is possible that additional PD-Ls exist 
on other cell types or are up-regulated on DCs by other 
stimuli. The defi  cits observed in PD-L1/L2−/− mice suggest 
that if additional PD-Ls exist, they either do not function 
to inhibit T cells or only function to regulate T cells in a 
restricted microenvironment.
These comparative analyses of PD-L1−/−, PD-L2−/−, 
and PD-L1/L2−/− mice demonstrate overlapping inhibi-
tory functions for PD-L1 and PD-L2 on APCs and a unique 
role for PD-L1 in tissue tolerance. The broad expression of 
PD-L1 in hematopoietic and nonhematopoietic tissues and the 
more restricted but overlapping expression of PD-L2 in DCs 
and macrophages may explain, in part, how these PD-Ls can 
have overlapping as well as unique functions. Our data show 
conclusively that the loss of PD-L1 in NOD mice results in 
increased diabetes and indicate that PD-L1 expression in the 
target organ protects against the initiation and progression of 
autoimmune diabetes. In diabetes, the inhibitory function of 
PD-L1 within the pancreas predominates over inhibitory func-
tions of PD-L1 and PD-L2 on APCs. PD-L1 and PD-L2 may 
have more subtle roles during the activation of self-reactive
T cells in lymphoid organs, but the unique expression of 
PD-L1 in the pancreas, together with inhibitory signals deliv-
ered by PD-L1 to eff  ector and naive T cells, may lead to the JEM VOL. 203, April 17, 2006  893
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predominant role for PD-L1 during autoimmune   diabetes. 
Our fi   ndings give impetus to the development of thera-
peutic approaches that exploit the PD-1–PD-L1 pathway for 
  controlling diabetes and/or islet transplant rejection.
MATERIALS AND METHODS
Mice. PD-L1−/− mice were generated as described previously (13). To 
generate PD-L2−/− mice, a PD-L2–targeting vector was electroporated 
into C57BL/6 ES cells. This targeting vector replaced the IgV exon of the 
PD-L2 gene with the hygromycin drug resistance gene. Homologous recom-
binants were identifi  ed by EcoRV digest and Southern blot analysis using 
a probe external to the genomic DNA used in the targeting vector. The 
probe was generated by PCR using the primers 5′-T  G  A  A  A  T  G  A  G  T  G  T  C  C-
T  G  A  C  T  G  -3′ and 5′-T  A  A  C  T  G  T  G  T  T  T  T  C  T  C  T  T  A  C  A  -3′. EcoRV digest 
yields a 28.6-kb band in WT and a 13.8-kb band in the targeted allele. 
Three PD-L2+/− ES clones were microinjected into blastocysts and gave 
rise to germline transmission of the PD-L2 mutation. Genotyping of mice 
was performed by PCR using the following primers. Primers to detect the 
IgV region deleted in PD-L2−/− mice were 5′-A  A  G  C  T  T  T  A  A  C  C  C  C  C-
G  T  T  A  C  C  T  T  G  A  -3′ and 5′-C  C  G  C  C  T  G  G  G  A  C  T  A  C  A  A  G  T  A  C  C  T  G-3′. 
Sequences of the Hygro primers were 5′-A  G  A  C  C  T  G  C  C  T  G  A  A  A  C  C-
G  A  A  C  -3′ and 5′-C  A  G  T  C  A  A  T  G  A  C  C  G  C  T  G  T  T  A  T  -3′. PCR products 
were 223 and 350 bp for PD-L2 and Hygro, respectively.
To generate PD-L1/L2−/− mice, PD-L1+/− C57BL/6 ES cells were 
retargeted with the PD-L2–targeting vector described in the previous 
paragraph. Hygromycin- and neomycin-resistant ES cells were selected, 
and homologous recombinants were identifi  ed by Southern blot analysis 
as described previously (15). C57BL/6 PD-L1+/−PD-L2+/− ES cells were 
microinjected into blastocysts and gave rise to germline transmission of 
both the PD-L1 and PD-L2 mutations. Because the PD-L1+/− ES cell 
clone was heterozygous for the PD-L1 deletion, the PD-L2 homologous 
recombination event could have occurred on the same chromosome 19 as 
the PD-L1 mutation or on the sister chromatid. We used the neomycin 
resistance and hygromycin resistance genes as markers for individual re-
combination events. Analysis of off  spring revealed two clones that gave rise 
to progeny in which the hygromycin resistance and neomycin resistance 
gene cosegregated, indicating that the PD-L1 and PD-L2 mutations were 
on the same chromosome. 
For DC and DO11 adoptive transfer studies, PD-L1−/−, PD-L2−/−, 
and PD-L1/L2−/− mice were backcrossed onto the BALB/c background 
for at least seven generations. In contrast to the fatal cardiomyopathy that 
develops in 4–6-wk-old PD-1−/− mice backcrossed onto the BALB/c back-
ground for 10 generations, we found no change in survival among WT, 
PD-L1−/−, PD-L2−/−, and PD-L1/L2−/− mice that had been backcrossed 
onto the BALB/c background for at least seven generations and monitored 
for up to 8 mo of age. Histological analyses of hearts in 2-mo-old mice from 
the three PD-L–defi  cient BALB/c strains did not reveal cellular infi  ltra-
tion or dilated cardiomyopathy (unpublished data). Littermate WT and WT 
BALB/c from Taconic were used as controls.
PD-L1/PD-L2−/− mice were backcrossed to NOD/MrkTac mice 
  (Taconic Farms). I-Ag7 was fi  xed by screening N3 breeders for I-Ag7. The 
backcross generation of the mice used in specifi  c experiments (N4, N5, or 
N7) is indicated in the fi  gure legends. WT littermates were used as controls 
for all experiments. Importantly, no Idd loci have been identifi  ed on chro-
mosome 19, upon which both PD-L1 and PD-L2 reside. PD-L1−/− (34) 
mice were speed backcrossed to NOD/LtJ (Jackson ImmunoResearch Labo-
ratories) and were confi  rmed to be homozygous for NOD Idd1, Idd2, Idd3, 
Idd4, Idd5a, Idd5b, Idd7, Idd8, Idd9, Idd10, Idd11, Idd12, Idd13, Idd14, and 
Idd15 loci. PD-L2−/− mice were speed backcrossed to NOD/MrkTac and 
were fi  xed at Idd1, Idd2, Idd3, Idd4, Idd9, Idd10, Idd11, Idd13, and Idd14 
loci. Both strains were  93% NOD (N4) upon intercrossing. Mice were 
monitored weekly for high urine glucose (Diastix; Bayer Pharmaceuticals). 
Positive glucosuria readings were confi  rmed by blood glucose measurement 
(Ascensia Elite; Bayer Pharmaceuticals). Diabetes was confi  rmed by three 
consecutive blood glucose measurements of ≥250 mg/dL. Harvard Medical 
School and Brigham and Women’s Hospital are accredited by the American 
Association of Accreditation of Laboratory Animal Care (AAALAC). Mice 
were maintained and used according to institutional and National Institutes 
of Health (NIH) guidelines in a pathogen-free facility. Islet transplant studies 
were performed at Massachusetts General Hospital (MGH), which is also 
accredited by AAALAC.
Mice were killed at 3, 4, or 6 wk of age or upon the onset of hyper-
glycemia. The ILN, PLN, pancreas, and spleen were removed and mashed 
through a 70-μm fi  lter (Falcon). For histology, the pancreas was preserved 
in Bouin’s fi  xative (Sigma-Aldrich), embedded in paraffi   n, and stained with 
hematoxylin and eosin. Islets were scored as peri-insulitic if mononuclear 
cells were outside the islet. Insulitic islets had varying degrees of mono-
nuclear infi  ltrates invading the islets. Normal islets had no mononuclear cells 
surrounding or within the islets.
Flow cytometry. Cells were stained for 30 min on ice in staining buff  er 
(2% BSA and 0.01% sodium azide) containing Fc block (eBioscience) and 
analyzed on a FACScalibur (Becton Dickinson). The following antibodies 
were used for staining: CD4 FITC, CD25 FITC, CD62L FITC, CD69 
FITC, GR-1 FITC, KJ126 FITC, CD4 PE, CD11b PE, DX5 PE, CD44 
PE, Vβ4 PE, IL-2 PE, IL-4 PE, CD3 PerCP-Cy5.5, CD4 PerCP-Cy5.5, 
CD8 PerCP-Cy5.5, B220 PerCP-Cy5.5, IFN-γ APC, CD25 APC (all from 
BD Biosciences), F4/80 FITC, CD8 APC (Caltag), PD-L2 FITC, PD-L1 
PE, and PD-1 PE (eBioscience). Mouse PD-1 Ig was the gift of M. Collins 
(Wyeth Research, Cambridge, MA). Intracellular cytokine staining was per-
formed as previously described (35).
In vitro T cell activation. BM was harvested from the tibia and femur, 
and red blood cells were lysed. Cells were cultured in 10 ng/ml GM-CSF 
and 1 ng/ml IL-4 (R&D Systems) for 7 d. DCs were purifi  ed using a CD11c 
isolation kit (Miltenyi Biotec). DO11 T cells were purifi  ed from DO11.10 
TCR tg mice by a CD4+ T cell isolation kit (Miltenyi Biotec), stained with 
KJ126, and 104 KJ126+ DO11 cells were cultured 1:1 with purifi  ed DCs 
with 0.01–1 μg/ml OVA323–339 (Analytical Biotechnology Services). Unless 
noted, all cell culture was performed in C10 (RPMI-1640, 10% FBS, 2 mM 
l-glutamine, 2 mM Hepes, 100 U/ml penicillin/streptavidin, and 55 μM 
β-mercaptoethanol; all were purchased from Invitrogen except FBS [Sigma-
Aldrich]). Plates were pulsed with 1 μCi 3H-Thymidine (PerkinElmer) for 
the last 6 h on day 3 or 5 of stimulation. Cytokines were assayed by culturing 
105 KJ126+DO11 cells with 105 DCs in a 24-well plate with 1 μg/ml OVA 
peptide. Supernatants were harvested every 24 h and assayed for cytokines 
by ELISA (eBioscience) as previously described (13). Detection limits were 
as follows: 10 pg/ml IL-2, 20 pg/ml IL-4, and 20 pg/ml IFN-γ.
DO11 adoptive transfer. Two million DO11 cells were purifi  ed and 
transferred i.v. via tail vein injection. On the following day, mice were 
immunized with 100 μg OVA (Sigma-Aldrich) emulsifi  ed in IFA (Sigma-
  Aldrich) in the hind footpads. Popliteal and ILNs were harvested on day 5 
and stained for KJ126 and CD4. 105 DO11 cells from immunized mice 
were restimulated as a whole LN culture in 24-well plates with 1 μg/ml 
OVA323–339. Supernatant was collected every 24 h and assayed for cytokines. 
Intracellular cytokine staining was performed on day 3.
NOD SCID adoptive transfer experiments. PD-L1/PD-L2+/− mice 
backcrossed to NOD four times were crossed to NOD/MrkBomTac-
  Prkdcscid mice (Taconic) and intercrossed to generate WT NOD SCID and 
PD-L1/PD-L2−/− NOD SCID mice of the same N5 generation. WT NOD 
N5 mice were used as donors in adoptive transfer experiments. Donor mice 
were confi  rmed to be euglycemic (typically 100–120 mg/dL) or hyperglyce-
mic (≥250 mg/dL) by blood glucose measurement. All recipient mice (both 
PD-L1/PD-L2−/− and WT NOD SCID) were given cells from pooled WT 
donors to minimize variability. For splenocyte adoptive transfer, spleens 
were removed and mashed through a 70-μm fi  lter, the red blood cells were 
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were washed twice in RPMI and counted. Splenocytes were resuspended 
to 20 × 107 cells/ml, and 100 μl was injected into the tail vein of a sex-
matched WT NOD SCID or PD-L1/PD-L2−/− NOD SCID mouse.
For the adoptive transfer of T cells, the spleen, ILNs, and PLNs were 
taken from nondiabetic donor mice. CD4+ and CD8+ cells were isolated by 
positive selection using MACS (Miltenyi Biotec) beads and columns. Purity 
was assessed by FACS and was generally >98%. 10 million T cells (isolated 
CD4+ and CD8+ lymphocytes) were transferred by i.v. injection into WT 
NOD SCID, PD-L1/PD-L2−/− NOD SCID, or BM chimera recipients. 
For the adoptive transfer of diabetogenic CD4+ T cells, the ILN, PLN, and 
spleen were harvested from diabetic WT mice. CD4+ T cells were posi-
tively selected using CD4 beads and MACS columns. Five million CD4+ 
T cells were adoptively transferred into WT NOD SCID or PD-L1/PD-
L2−/− NOD SCID recipients. After transfer, recipient mice were monitored 
twice weekly for glucosuria, and positive readings were confi  rmed by blood 
glucose measurement. Upon the onset and confi  rmation of hyperglycemia, 
mice were killed, and the ILN, PLN, pancreas, and spleen were removed 
and analyzed by fl  ow cytometry and histology.
For the adoptive transfer of BDC2.5 TCR tg+ T cells, N7 donors were 
used. Lymphocytes were isolated from all LNs and spleen, and red blood cells 
were lysed and enriched for CD4 T cells by the depletion of MHC II and 
CD8 T cells before staining for CD62L, CD4, and CD25. Cells were sorted 
into a CD4+CD25−CD62Lhi fraction and adoptively transferred into WT 
NOD SCID or PD-L1/PD-L2−/− NOD SCID recipients. For these experi-
ments, recipients were monitored daily after 7 d for the onset of diabetes.
Islet transplantation. NOD SCID mice and NOD SCID/PD-L1/PD-
L2−/−mice at 10–12 wk of age were used as donors for islet transplants. 
Islets were isolated using a modifi  cation of a method in which the pancreatic 
duct is distended with collagenase P (36). After purifi  cation on a Histopaque 
gradient (HistopaqueR-1077; Sigma-Aldrich), islets with diameters between 
75 and 250 μm were hand picked and transplanted under the renal capsule. 
Each recipient received 800–1,000 islets.
Upon the onset of hyperglycemia (three consecutive blood glucose re-
sults of >300 mg/dl, according to an established protocol at MGH), the host 
pancreas and the grafted kidney were fi  xed in 10% formalin fi  xative. The 
kidney grafts were cross sectioned through the entire graft at 4-μm intervals, 
and alternate sections were stained with hematoxylin and eosin for routine 
assessment of the infi  ltrate. The remaining sections were stained for insulin, 
glucagon, and somatostatin cells. All specimens were coded and randomized, 
and blinded analysis of the sections was performed. Islet grafts and graft infi  l-
tration were scored on a scale of zero to four.
BM chimeras. BM was isolated from PD-L1/PD-L2−/− NOD SCID or 
WT NOD SCID donor animals, and cell clumps were removed. Cells were 
adjusted to 5 × 107 cells/ml in PBS. PD-L1/PD-L2−/− NOD SCID recipi-
ents were lethally irradiated with two doses of 150 rads given at least 2 h
apart (37). Mice were i.v. injected immediately after the second radiation 
dose with 5 × 106 cells. Chimerism was confi  rmed by evaluating PD-L1 
expression on splenic CD11c+CD3− DCs. The numbers of DCs were cal-
culated by multiplying CD11c+ lineage-negative cells by the total cell yield. 
At least 8 wk after irradiation and BM reconstitution, BM chimeras were 
given 107 WT NOD T cells i.v. Mice were monitored twice weekly for the 
development of diabetes. Upon diabetes onset, mice were killed, and the 
spleen, PLN, and ILN were removed and analyzed by fl  ow cytometry.
Online supplemental material. Fig. S1 shows the PD-L1– and PD-L2–
targeting vectors and a strategy for generation of the PD-L2−/− and PD-L1/
L2−/− mouse strains. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20051776/DC1.
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